Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Current Report · Items 5.07, 9.01 · 8-K

Palatin Technologies, Inc.

PTNNASDAQEQUITYCurrent

Submission of Matters to a Vote of Security Holders

Item 5.07 Submission of Matters to a Vote of Security Holders. On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following:…

Filed Aug 3, 2026Accepted Aug 3, 2026, 6:04 AM EDTCIK 911216Accession 0001493152-26-035722
Share

Company context

We are a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor systems. Our product candidates are targeted, receptor-specific therapeutics for the treatment of diseases with significant unmet medical need and commercial potential.

Current securities

Historical securities (3)

Recent company filings

  1. 10-K filingSep 28, 2026
  2. SCHEDULE 13G/A filingAug 14, 2026
  3. DEF 14A filingJun 25, 2026
  4. CERT filingMay 28, 2026
  5. 8-A12B filingMay 28, 2026

Disclosure sections

Items 5.07, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 5.07Item 5.07 - Submission of Matters to Vote
Item 5.07 Submission of Matters to a Vote of Security Holders. On July 28, 2026, Palatin Technologies, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) to consider and vote on the following: (1) election of directors (“Item 1”), (2) ratification of the appointment of the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2026 (“Item 2”), (3) approval of an amendment to the Company’s 2011 Stock Incentive Plan, as amended and restated, to increase the number of shares available for equity awards by 260,000 shares (“Item 3”), and (4) advisory approval of the compensation of the Company’s named executive officers for the fiscal year ended June 30, 2025 (“Item 4”). As of June 22, 2026 (the “Record Date”), the total number of votes entitled to be cast at the Annual Meeting was 1,842,625, consisting of (i) 1,779,275 shares of Common Stock or equivalents thereof, each share entitled to one vote, (ii) 4,030 shares of Series A Preferred Stock, each share entitled to approximately 0.38 votes, representing an aggregate of 1,534 votes, and (iii) 3,400 shares of Series D Preferred Stock, each share entitled to approximately 18.18 votes per share, representing an aggregate of 61,816 votes. At the Annual Meeting, the total number of votes present in person or by proxy was 1,000,506, comprising 54.3% of the votes entitled to be cast at the Annual Meeting.